Patents Assigned to VACCIBODY AS
-
Publication number: 20220111023Abstract: The present invention relates to an anticancer neoepitope composition comprising polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The anticancer neoepitope composition comprising a DNA polynucleotide comprising a nucleotide sequence encoding an antigenic unit comprising from 2 to 50 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a linker and a terminal antigenic subunit comprising at least a part of a cancer neoepitope sequence.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Applicant: VACCIBODY ASInventor: Agnete Brunsvik Fredriksen
-
Publication number: 20210388438Abstract: The present invention relates to a method for selecting neoepitopes for an individual, by selecting MHC I and/or MHC II binding neoepitopes and ranking them with respect the methods as described herein.Type: ApplicationFiled: September 27, 2019Publication date: December 16, 2021Applicant: VACCIBODY ASInventors: Monika Sekelja, Karoline Schjetne, Agnete Brunsvik Fredriksen
-
Publication number: 20200239568Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: February 7, 2020Publication date: July 30, 2020Applicant: Vaccibody ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Patent number: 10590195Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: June 24, 2011Date of Patent: March 17, 2020Assignee: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20190022202Abstract: The present invention relates to an anticancer vaccine comprising polynucleotides or polypeptides, methods of treatment of targeting module cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine comprises a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit, wherein said antigenic unit comprises n?1 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a second linker and said antigenic unit further comprising a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50, or the vaccine comprises a polypeptide encoded by the polynucleotide or a dimeric protein consisting of two polypeptides encoded by the polynucleotide.Type: ApplicationFiled: January 5, 2017Publication date: January 24, 2019Applicant: VACCIBODY ASInventors: Stine Granum, Elisabeth Stubsrud, Agnete Brunsvik Fredriksen
-
Publication number: 20190015491Abstract: The present invention relates to an anticancer vaccine comprising polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine comprises a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit, wherein said antigenic unit comprises n-1 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a second linker and said antigenic unit further comprising a final cancer neoepitope sequence, wherein n is an integer of from 3 to 50, or the vaccine comprises a polypeptide encoded by the polynucleotide or a dimeric protein consisting of two polypeptides encoded by the polynucleotide.Type: ApplicationFiled: January 5, 2017Publication date: January 17, 2019Applicant: VACCIBODY ASInventor: Agnete Brunsvik Fredriksen
-
Patent number: 9901635Abstract: The present invention relates to therapeutic compounds, such as vaccines against human papillomavirus (HPV) and in particular to DNA vaccines against HPV16 or HPV18. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment of various HPV induced diseases, such as cancers and infectious diseases by application.Type: GrantFiled: December 20, 2012Date of Patent: February 27, 2018Assignee: Vaccibody ASInventors: Ole Henrik Brekke, Agnete Brunsvik Fredriksen, Ali Areffard, Mona Mari Lindeberg
-
Publication number: 20180030155Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: October 12, 2017Publication date: February 1, 2018Applicant: Vaccibody ASInventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
-
Patent number: 9796787Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: October 1, 2015Date of Patent: October 24, 2017Assignee: Vaccibody A/SInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Publication number: 20160031991Abstract: The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Applicant: VACCIBODY ASInventors: Ole Henrik BREKKE, Mona Mari LINDEBERG, Agnete Brunsvik FREDRIKSEN
-
Patent number: 9169322Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: January 19, 2012Date of Patent: October 27, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Patent number: 8932603Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: February 25, 2004Date of Patent: January 13, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
-
Publication number: 20130336971Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: June 24, 2011Publication date: December 19, 2013Applicant: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20130171140Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: June 24, 2011Publication date: July 4, 2013Applicant: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20120171242Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: January 19, 2012Publication date: July 5, 2012Applicant: VACCIBODY ASInventors: Bjarne BOGEN, Agnete Brunsvik Fredriksen, Inger SANDLIE